logo
  Join        Login             Stock Quote

Antares Pharma (ATRS) Gains After FDA Accepts NDA For Rheumatoid Arthritis, Psoriasis Treatment

 February 27, 2013 08:28 AM
 


(By Balaseshan) Antares Pharma Inc. (NASDAQ: ATRS) shares jumped 7.42% in premarket after the U.S. Food and Drug Administration (FDA) has accepted its new drug application for treatment of rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis.

The FDA indicated that the application is sufficiently complete to permit a substantive review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of October 14, ten months from the official NDA filing. The PDUFA date is the target date for the FDA to complete its review of the NDA.

Otrexup is a potential new product for the subcutaneous delivery of methotrexate (MTX) using Medi-Jet technology. Otrexup is being developed for self-administration of MTX to enhance the treatment of rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis.

[Related -Six Stocks That Could Get An October Bump From The FDA]

Studies conducted to date indicate Otrexup is safe, easy and comfortable for RA patients to self-administer precise subcutaneous doses of MTX with improved systemic availability compared to oral doses.

Rheumatoid Arthritis is a form of inflammatory arthritis and an autoimmune disease. In rheumatoid arthritis, the immune system – which is designed to protect health by attacking foreign cells such as viruses and bacteria – instead attacks the body's own tissues, specifically the synovium, a thin membrane that lines the joints.

Psoriasis is a chronic, autoimmune disease that appears on the skin. It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis is not contagious. According to the National Psoriasis Foundation, as many as 7.5 million Americans have psoriasis.

[Related -Stocks Jump Over 1 Pct On Strong Housing Data; Dollar Tree (DLTR) Jumps]

ATRS closed Tuesday's regular session up 0.30% at $3.37. The stock has been trading between $2.51 and $5.58 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageChart Says This Retailer's Comeback Isn't Finished

One of the surprises, at least on the surface, of the market's recent swoon was the outperformance of read on...

article imageETF Performance Review: Major Asset Classes | 19 Dec 2014

It’s all about real estate investment trusts (REITs) these days when it comes to bullish performance among read on...

article imageOil and Global Stock Markets Rebounding Sharply

So far so good on our expectation of a 4 to 5% pullback and then a resumption of the bull read on...

article imageGrading the FOMC

Love its members or loathe them, you have to admire the gradual impact the policy-making committee has had read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.